The Latest Breaking News from AbbVie

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

Amid ongoing market uncertainty, Morgan Stanley believes these three defensive dividend-paying stocks could be ideal buys now.

In today's volatile market, dividend stocks remain one of the safest choices.

Explore three defensive stock picks from the consumer staples, healthcare, and utilities sectors that offer stability amid market uncertainty in August.

Consider these stock and fund picks now that the Federal Reserve's rate-cutting campaign is underway.

The S&P 500 is down a staggering $3.2 trillion in the market implosion since mid-July. But some investors are dodging the pain.

Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.

These companies have consistently paid and increased their dividends, and they have a growing earnings base to support their future payouts.